Limits...
LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma.

Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, Wang S, Zhou F, Shi S, Feng X, Sun N, Liu Z, Skogerboe G, Dong J, Yao R, Zhao Y, Sun J, Zhang B, Yu Y, Shi X, Luo M, Shao K, Li N, Qiu B, Tan F, Chen R, He J - Gut (2014)

Bottom Line: Long non-coding RNAs (lncRNAs) are often found to have important regulatory roles.LncRNAs showed significantly altered expression in OSCC tissues.Our results suggest that the three-lncRNA signature is a new biomarker for the prognosis of patients with OSCC, enabling more accurate prediction of survival.

View Article: PubMed Central - PubMed

Affiliation: ! Department of Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, The People's Republic of China.

Show MeSH

Related in: MedlinePlus

Survival prediction in stage II and III patients. Kaplan–Meier survival curves of stage II and III patients with OSCC classified into high- and low-risk groups based on the three-lncRNA signature. (A) Stage II patients, training set (n=22). (B) Stage II patients, combined test set and independent cohort (n=55). (C) Stage III patients, training set (n=36). (D) Stage III patients, combined test set and independent cohort (n=56). OSCC, oesophageal squamous cell carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4215280&req=5

GUTJNL2013305806F4: Survival prediction in stage II and III patients. Kaplan–Meier survival curves of stage II and III patients with OSCC classified into high- and low-risk groups based on the three-lncRNA signature. (A) Stage II patients, training set (n=22). (B) Stage II patients, combined test set and independent cohort (n=55). (C) Stage III patients, training set (n=36). (D) Stage III patients, combined test set and independent cohort (n=56). OSCC, oesophageal squamous cell carcinoma.

Mentions: We next carried out a stratified analysis in TNM stage II and III patients to evaluate whether the three-lncRNA signature could predict survival of patients within the same clinical stage. Log-rank test of stage II patients in both the training group (p<0.0001, figure 4A) and the combination of test and independent cohort (p=0.0257, figure 4B) showed that the signature could classify stage II patients with OSCC into high- and low-risk groups. For patients with stage III OSCC, the three-lncRNA signature showed similar prognostic value in the training (p=0.0104, figure 4C) and the combined test and independent (p=0.0105, figure 4D) datasets. Because of limited sample size (n=10), the stratified analysis was not performed for stage I patients.


LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma.

Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, Wang S, Zhou F, Shi S, Feng X, Sun N, Liu Z, Skogerboe G, Dong J, Yao R, Zhao Y, Sun J, Zhang B, Yu Y, Shi X, Luo M, Shao K, Li N, Qiu B, Tan F, Chen R, He J - Gut (2014)

Survival prediction in stage II and III patients. Kaplan–Meier survival curves of stage II and III patients with OSCC classified into high- and low-risk groups based on the three-lncRNA signature. (A) Stage II patients, training set (n=22). (B) Stage II patients, combined test set and independent cohort (n=55). (C) Stage III patients, training set (n=36). (D) Stage III patients, combined test set and independent cohort (n=56). OSCC, oesophageal squamous cell carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4215280&req=5

GUTJNL2013305806F4: Survival prediction in stage II and III patients. Kaplan–Meier survival curves of stage II and III patients with OSCC classified into high- and low-risk groups based on the three-lncRNA signature. (A) Stage II patients, training set (n=22). (B) Stage II patients, combined test set and independent cohort (n=55). (C) Stage III patients, training set (n=36). (D) Stage III patients, combined test set and independent cohort (n=56). OSCC, oesophageal squamous cell carcinoma.
Mentions: We next carried out a stratified analysis in TNM stage II and III patients to evaluate whether the three-lncRNA signature could predict survival of patients within the same clinical stage. Log-rank test of stage II patients in both the training group (p<0.0001, figure 4A) and the combination of test and independent cohort (p=0.0257, figure 4B) showed that the signature could classify stage II patients with OSCC into high- and low-risk groups. For patients with stage III OSCC, the three-lncRNA signature showed similar prognostic value in the training (p=0.0104, figure 4C) and the combined test and independent (p=0.0105, figure 4D) datasets. Because of limited sample size (n=10), the stratified analysis was not performed for stage I patients.

Bottom Line: Long non-coding RNAs (lncRNAs) are often found to have important regulatory roles.LncRNAs showed significantly altered expression in OSCC tissues.Our results suggest that the three-lncRNA signature is a new biomarker for the prognosis of patients with OSCC, enabling more accurate prediction of survival.

View Article: PubMed Central - PubMed

Affiliation: ! Department of Thoracic Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, The People's Republic of China.

Show MeSH
Related in: MedlinePlus